Long COVID treatment options span salt loading, ivabradine, low-dose naltrexone and probiotics

Long COVID, or post-acute sequelae of SARS-CoV-2 infection, affects roughly 10% of infected people, which the authors estimate at more than 77 million cases worldwide. It often involves fatigue, cognitive impairment, and autonomic problems such as postural orthostatic tachycardia syndrome (POTS) and inappropriate sinus tachycardia. Because symptoms vary so widely and no standardized guidelines exist, treatment is largely symptomatic. This narrative review synthesizes the mechanisms and the evidence for lifestyle, drug, and probiotic approaches.

The authors searched PubMed and Google Scholar through January 2025. They included clinical studies, randomized trials, cohort studies, case series, and reviews. Proposed mechanisms include persistent viral material in the gut, brain, and lymph nodes; elevated autoantibodies and T cell dysregulation; raised CRP, IL-6, and TNF-α; fibrin amyloid microclots that impair oxygen delivery; and mitochondrial dysfunction with excess reactive oxygen species, a shift toward glycolysis, and reduced ATP. Microglial activation and blood-brain barrier disruption are also implicated. Gut dysbiosis shows depletion of short-chain fatty acid producers such as Faecalibacterium, Eubacterium hallii, and Coprococcus.

Non-pharmacological measures are presented as first-line. In a 3-month online exercise program in 62 patients, those with moderate fatigue improved performance, while those with severe fatigue gained little. For POTS, patients are advised to drink 2–3 L of water daily and titrate sodium from about 6 g to 10–12 g per day under supervision. High-fiber diets improved GI symptoms in a case report. Protein targets of 1.0–1.5 g/kg/day are suggested. In a retrospective study of 86 patients, high adherence to pacing predicted significantly greater recovery.

For drugs, propranolol (10–20 mg up to four times daily) and calcium channel blockers are used for tachycardia but are often poorly tolerated. Ivabradine improved symptoms within 7 days in an observational COVID-POTS study. In a randomized, double-blind crossover trial of 22 patients with hyperadrenergic POTS, ivabradine improved quality-of-life measures without bradycardia or hypotension. Pyridostigmine improved orthostatic intolerance scores, with mental health benefits mainly in combination with propranolol. Low-dose naltrexone (4.5 mg/day) plus NAD+ patches reduced fatigue and improved quality of life over 12 weeks in 36 patients, and cohorts of 59 and 108 patients showed benefits for fatigue and pain. High-dose IVIG helped in small case series.

Probiotic evidence is the review's focus. In a 200-participant randomized, placebo-controlled trial, an enzyme complex (ImmunoSEB) plus Bacillus coagulans, B. subtilis, and B. clausii (ProbioSEB CSC3) resolved fatigue in 91% versus 15% on placebo at day 14, with no adverse effects reported. In a 38-person trial, VSL#3 improved physical functioning, fatigue, and GI symptoms but not anxiety, depression, or somatization. A six-patient pilot of heat-killed paraprobiotics reduced fatigue, depression, and dysautonomia and lowered TLR2 expression on T cells.

The authors conclude that no FDA-approved long COVID therapy exists and call for large randomized trials. Key caveats are that most drug and probiotic data come from small, uncontrolled, or retrospective studies. The 91% vs. 15% effect is unusually large and needs independent replication. Fermented foods and prebiotics are suggested as complements, but they were not tested in the cited trials.